The Regulation of Clinical Stem Cell Research in China

Regulating clinical stem cell research, which has been one of the most ethically controversial technologies of the present age, is an unenviable task for China. The ambit of the Administrative Measure is wide. The Chinese government hopes to rein the clinical stem cell research with the enforcement of the new order. However, the legal framework of clinical stem cell therapy leaves a door open for untested and unverified stem cell therapies. And it is still an open question whether the combination of the Ministry of Health and CFDA is capable of enforcing the Administrative Measures on hospitals.